
TSBX
Turnstone Biologics Corp
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.3601
Open
0.3601
VWAP
--
Vol
--
Mkt Cap
69.15M
Low
0.3601
Amount
--
EV/EBITDA(TTM)
--
Total Shares
23.13M
EV
-8.47M
EV/OCF(TTM)
--
P/S(TTM)
--
Turnstone Biologics Corp. is a biotechnology company. The Company has been focused on the development of a differentiated approach to treating and curing patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy. It has discontinued all sponsored clinical studies evaluating TIDAL-01 for all indications, and pursuit of strategic alternatives to enhance and preserve stockholder value, which may include exploration and evaluation of strategic options like a merger, reverse merger, other business combinations, sale of assets, licensing, or other strategic transactions.
Show More
Valuation Metrics
The current forward P/E ratio for Turnstone Biologics Corp (TSBX.O) is -0.63, compared to its 5-year average forward P/E of -0.83. For a more detailed relative valuation and DCF analysis to assess Turnstone Biologics Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-0.83
Current PE
-0.63
Overvalued PE
0.05
Undervalued PE
-1.71
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
0.16
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.88
Undervalued EV/EBITDA
-0.57
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q2
0.00
Total Revenue
FY2025Q2
YoY :
-83.41%
-3.66M
Operating Profit
FY2025Q2
YoY :
-74.23%
-5.49M
Net Income after Tax
FY2025Q2
YoY :
-73.91%
-0.24
EPS - Diluted
FY2025Q2
YoY :
-73.15%
-4.30M
Free Cash Flow
FY2025Q2
N/A
Gross Profit Margin - %
FY2025Q2
N/A
FCF Margin - %
FY2025Q2
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
TSBX News & Events
Events Timeline
2025-08-11 (ET)
2025-08-11
09:09:02
Xoma closes tender offer for Turnstone Biologics

2025-06-27 (ET)
2025-06-27
07:36:08
Xoma to acquire Turnstone Biologics for $0.34 in cash per share

2025-03-30 (ET)
2025-03-30
17:40:46
Turnstone Biologics reports Q4 EPS (56c) vs (73c) last year

Sign Up For More Events
Sign Up For More Events
News
7.0
07-05GlobenewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GMS, TSBX, BGFV on Behalf of Shareholders
7.0
06-30Globenewswire$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Turnstone Biologics Corp. (NASDAQ: TSBX)
8.5
06-27NASDAQ.COMXOMA To Acquire Turnstone Biologics For $0.34/Shr Plus Contingent Value Right
Sign Up For More News
People Also Watch

BCDA
BioCardia Inc
1.740
USD
0.00%

LRHC
La Rosa Holdings
5.640
USD
+1.62%

GSIW
Garden Stage Ltd
0.124
USD
-2.37%

CLWT
Euro Tech Holdings Company Ltd
1.234
USD
0.00%

INDP
Indaptus Therapeutics Inc
8.240
USD
0.00%

WATT
Energous Corp
7.300
USD
+1.11%

PSIG
PS International Group Ltd
0.335
USD
0.00%

BREA
Brera Holdings PLC
6.550
USD
0.00%

APDN
Applied DNA Sciences Inc
3.960
USD
-2.46%

CLRB
Cellectar Biosciences Inc
4.500
USD
-2.39%
FAQ

What is Turnstone Biologics Corp (TSBX) stock price today?
The current price of TSBX is 0.3601 USD — it has increased 1.41 % in the last trading day.

What is Turnstone Biologics Corp (TSBX)'s business?

What is the price predicton of TSBX Stock?

What is Turnstone Biologics Corp (TSBX)'s revenue for the last quarter?

What is Turnstone Biologics Corp (TSBX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Turnstone Biologics Corp (TSBX)'s fundamentals?

How many employees does Turnstone Biologics Corp (TSBX). have?
